Comparison of the clonogenic survival of A549 non-small cell lung adenocarcinoma cells after irradiation with low-dose-rate beta particles and high-dose-rate X-rays. 2012

Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
Department of Physics, University of Namur, Belgium. anne-catherine.wera@fundp.ac.be

OBJECTIVE Lung cancer is the leading cause of cancer-related death. Among the new modalities to treat cancer, internal radiotherapy seems to be very promising. However, the achievable dose-rate is two orders of magnitude lower than the one used in conventional external radiotherapy, and data has to be collected to evaluate the cell response to highlight the potential effectiveness of low-dose-rate beta particles irradiation. This work investigates the phosphorus beta irradiation ((32)P) dose response on the clonogenicity of human A549 non-small cell lung adenocarcinoma cells and compares it to high-dose-rate X-irradiations results. METHODS Cell survival was evaluated by a colony forming assay eight days after low-dose-rate (32)P beta irradiations (0.8 Gy/h) and high-dose-rate X-ray irradiations (0.855 Gy/min). RESULTS Survival curves were obtained for both types of irradiations, and showed hyper-radiosensitivity at very low doses. Radiosensitivity parameters were obtained by using the linear-quadratic and induced-repair models. CONCLUSIONS Comparison with high-dose-rate X-rays shows a similar surviving fraction, confirming the effectiveness of beta particles for tumor sterilization.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010761 Phosphorus Radioisotopes Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes. Radioisotopes, Phosphorus
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D001610 Beta Particles High energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus. Beta Rays,Beta Radiation,Radiation, Beta,Beta Particle,Beta Radiations,Beta Ray,Particle, Beta,Particles, Beta,Radiations, Beta,Ray, Beta,Rays, Beta
D014965 X-Rays Penetrating electromagnetic radiation emitted when the inner orbital electrons of an atom are excited and release radiant energy. X-ray wavelengths range from 1 pm to 10 nm. Hard X-rays are the higher energy, shorter wavelength X-rays. Soft x-rays or Grenz rays are less energetic and longer in wavelength. The short wavelength end of the X-ray spectrum overlaps the GAMMA RAYS wavelength range. The distinction between gamma rays and X-rays is based on their radiation source. Grenz Ray,Grenz Rays,Roentgen Ray,Roentgen Rays,X Ray,X-Ray,Xray,Radiation, X,X-Radiation,Xrays,Ray, Grenz,Ray, Roentgen,Ray, X,Rays, Grenz,Rays, Roentgen,Rays, X,X Radiation,X Rays,X-Radiations

Related Publications

Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
March 2013, Radiation research,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
January 2009, Physics in medicine and biology,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
January 1999, Cardiovascular radiation medicine,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
July 2003, Radiation and environmental biophysics,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
November 2013, Radiation research,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
January 2012, Brachytherapy,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
February 2017, Nuklearmedizin. Nuclear medicine,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
March 1983, Radiation research,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
January 2015, PloS one,
Anne-Catherine Wéra, and Celine Borlon, and Vincent E Nuttens, and Helene Riquier, and Olivier Feron, and Carine Michiels, and Stephane Lucas
January 2013, Oncology letters,
Copied contents to your clipboard!